Similar articles for PMID: 35393349

Year	Number of Results
1990	1
1996	1
1998	2
2002	1
2003	1
2005	4
2006	2
2007	2
2010	1
2012	2
2013	5
2014	2
2015	5
2016	5
2017	7
2018	5
2019	9
2020	20
2021	26
2022	13

1

The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective.

Lee ST, Emmett LM, Pattison DA, Hofman MS, Bailey DL, Latter MJ, Francis RJ, Scott AM. Lee ST, et al. J Nucl Med. 2022 Jun;63(6):819-822. doi: 10.2967/jnumed.122.263996. Epub 2022 Apr 7. J Nucl Med. 2022. PMID: 35393349

2

Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [¹⁸F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0.

Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, Sachpekidis C, Humbert O, Gheysens O, Glaudemans AWJM, Weber W, Wahl RL, Scott AM, Pandit-Taskar N, Aide N. Lopci E, et al. Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2323-2341. doi: 10.1007/s00259-022-05780-2. Epub 2022 Apr 4. Eur J Nucl Med Mol Imaging. 2022. PMID: 35376991 Free PMC article.

3

Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.

Miller C, Rousseau J, Ramogida CF, Celler A, Rahmim A, Uribe CF. Miller C, et al. Theranostics. 2022 Jan 1;12(1):232-259. doi: 10.7150/thno.62851. eCollection 2022. Theranostics. 2022. PMID: 34987643 Free PMC article. Review.

4

Emerging Preclinical and Clinical Applications of Theranostics for Nononcological Disorders.

Assadi M, Jokar N, Yordanova A, Gholamrezanezhad A, Amini A, Abbasi F, Biersack HJ, Amini A, Nabipour I, Ahmadzadehfar H. Assadi M, et al. PET Clin. 2021 Jul;16(3):429-440. doi: 10.1016/j.cpet.2021.03.009. PET Clin. 2021. PMID: 34053586 Review.

5

Theranostic approaches in nuclear medicine: current status and future prospects.

Filippi L, Chiaravalloti A, Schillaci O, Cianni R, Bagni O. Filippi L, et al. Expert Rev Med Devices. 2020 Apr;17(4):331-343. doi: 10.1080/17434440.2020.1741348. Epub 2020 Mar 19. Expert Rev Med Devices. 2020. PMID: 32157920 Review.

6

Bench-to-Bedside Theranostics in Nuclear Medicine.

Jokar N, Assadi M, Yordanova A, Ahmadzadehfar H. Jokar N, et al. Curr Pharm Des. 2020;26(31):3804-3811. doi: 10.2174/1381612826666200218104313. Curr Pharm Des. 2020. PMID: 32067609 Review.

7

Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.

Gomes Marin JF, Nunes RF, Coutinho AM, Zaniboni EC, Costa LB, Barbosa FG, Queiroz MA, Cerri GG, Buchpiguel CA. Gomes Marin JF, et al. Radiographics. 2020 Oct;40(6):1715-1740. doi: 10.1148/rg.2020200021. Radiographics. 2020. PMID: 33001789 Review.

8

SNMMI Procedure Standard/EANM Practice Guideline on Pediatric ¹⁸F-FDG PET/CT for Oncology 1.0.

Vali R, Alessio A, Balza R, Borgwardt L, Bar-Sever Z, Czachowski M, Jehanno N, Kurch L, Pandit-Taskar N, Parisi M, Piccardo A, Seghers V, Shulkin BL, Zucchetta P, Lim R. Vali R, et al. J Nucl Med. 2021 Jan;62(1):99-110. doi: 10.2967/jnumed.120.254110. J Nucl Med. 2021. PMID: 33334912 Free PMC article.

9

General Concepts in Theranostics.

Nunes RF, Zuppani RMF, Coutinho AM, Barbosa FG, Sapienza MT, Marin JFG, Buchpiguel CA. Nunes RF, et al. PET Clin. 2021 Jul;16(3):313-326. doi: 10.1016/j.cpet.2021.03.010. PET Clin. 2021. PMID: 34053576 Review.

10

^203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer.

Li M, Sagastume EA, Lee D, McAlister D, DeGraffenreid AJ, Olewine KR, Graves S, Copping R, Mirzadeh S, Zimmerman BE, Larsen RH, Johnson FL, Schultz MK. Li M, et al. Curr Med Chem. 2020;27(41):7003-7031. doi: 10.2174/0929867327999200727190423. Curr Med Chem. 2020. PMID: 32720598 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed